TriSalus Life Sciences (NASDAQ: TLSI) shares preliminary 2025 results and 2026 revenue guidance

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. filed a current report to note that it issued a press release with preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025, along with 2026 revenue guidance. The company attached this press release as Exhibit 99.1 and incorporated it by reference for informational purposes. The report also clarifies that the press release and related information are being furnished rather than filed, which limits their exposure to certain securities law liabilities.

0001826667FALSE00018266672026-01-122026-01-120001826667us-gaap:CommonStockMember2026-01-122026-01-120001826667us-gaap:WarrantMember2026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

TRISALUS LIFE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-39813			85-3009869
(State or other jurisdiction of incorporation or organization)			(Commission File Number)			(I.R.S. Employer Identification No.)
6272 W 91st Ave, Westminster, Colorado						80031
(Address of principal executive office)						(Zip Code)

(888) 321-5212

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
o			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, $0.0001 par value			TLSI			Nasdaq Global Market
Warrants, each whole warrant exercisable for one share of registrant's common stock at an exercise price of $11.50 per share			TLSIW			Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Conditions.

On January 12, 2026, TriSalus Life Sciences, Inc. (the “Company”) issued a press release announcing preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025 and 2026 revenue guidance. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

This information, including Exhibit 99.1, will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and it will not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing.

Item 9.01						Financial Statements and Exhibits.
(d) Exhibits:
Exhibit Number						Description
99.1						Press Release dated January 12, 2026
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 12, 2026			TriSalus Life Sciences, Inc.
			By:			/s/ David Patience
						Name:			David Patience
						Title:			Chief Financial Officer

FAQ

What did TriSalus Life Sciences (TLSI) disclose in this 8-K?

TriSalus Life Sciences disclosed that it issued a press release with preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, and provided 2026 revenue guidance.

Which period’s results does the TriSalus (TLSI) press release cover?

The press release covers preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025.

Did TriSalus (TLSI) include 2026 guidance in this disclosure?

Yes. The company stated that the press release includes 2026 revenue guidance.

Where can investors find the detailed TriSalus (TLSI) financial figures?

Detailed figures are contained in the press release attached as Exhibit 99.1 to the report and incorporated by reference.

Is the TriSalus (TLSI) press release considered filed with the SEC?

No. The company states that the information, including Exhibit 99.1, is furnished and will not be deemed filed for purposes of Section 18 of the Exchange Act.

Who signed the TriSalus (TLSI) 8-K related to the preliminary results?

The report was signed on behalf of TriSalus Life Sciences, Inc. by David Patience, Chief Financial Officer.